Valuation: Vectura Group

Market Cap 1B 883M 822M 755M 1.42B 96.34B 1.44B 9.77B 3.82B 47.57B 3.77B 3.69B 164B P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 930M 818M 761M 699M 1.31B 89.21B 1.33B 9.05B 3.53B 44.05B 3.49B 3.42B 152B EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
31/10/25 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
17/09/24 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
16/04/24 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
29/12/21 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
03/12/21 Philip Morris CEO does not need M&A to hit smoke free goals RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
5 years 150.2
Extreme 150.2
176
10 years 59.1
Extreme 59.1
180.88
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 01/06/2016
Corporate Secretary - 30/06/2025
Director TitleAgeSince
Director/Board Member 53 15/09/2023
Director/Board Member 57 30/06/2025
Date Insider Type Main position Quantity % Market Cap.
01/10/21 Fiscal year

Chief Executive Officer

1,311,395 0.2149%
01/10/21 Fiscal year 159,896 0.0262%
01/10/21 Fiscal year 1,928,114 0.3160%

Financials

2019 2020
Net sales 178M 157M 146M 134M 252M 17.1B 255M 1.73B 677M 8.44B 669M 655M 29.18B 191M 168M 156M 143M 269M 18.28B 273M 1.85B 724M 9.03B 715M 700M 31.2B
Net income -22.1M -19.43M -18.09M -16.61M -31.19M -2.12B -31.6M -215M -83.96M -1.05B -82.96M -81.17M -3.62B 122M 108M 100M 91.99M 173M 11.74B 175M 1.19B 465M 5.8B 459M 450M 20.03B
Net Debt -66.5M -58.46M -54.42M -49.98M -93.84M -6.38B -95.08M -647M -253M -3.15B -250M -244M -10.88B -74.4M -65.41M -60.88M -55.91M -105M -7.13B -106M -724M -283M -3.52B -279M -273M -12.18B
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-